Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer
A Phase 2 trial is investigating the efficacy and safety of botensilimab and balstilimab in patients with unresectable colorectal adenocarcinoma.
Phase II
Oncology / Immunotherapy
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase 2 trial of botensilimab and balstilimab represents a significant opportunity for Agenus Inc. to establish a foothold in the competitive landscape of colorectal cancer therapies. Monitoring the trial's outcomes is crucial for assessing the potential impact on treatment options and market positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results on survival rates and quality of life metrics, as well as safety data.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.